<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104006">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01660061</url>
  </required_header>
  <id_info>
    <org_study_id>EV 77/11</org_study_id>
    <nct_id>NCT01660061</nct_id>
  </id_info>
  <brief_title>Monitoring Anticoagulant Therapy in Antiphospholipid Syndrome</brief_title>
  <official_title>Monitoring Anticoagulant Therapy With Vitamin-K Antagonists in Patients With Antiphospholipid Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospitals</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To Assess the Influence of Antiphospholipid Antibodies on INR Test Results in Patients with
      the Antiphospholipid Syndrome Anticoagulated with Vitamin-K Antagonists.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with an antiphospholipid syndrome receiving Vitamin-K antagonists for secondary
      prevention after a first thrombotic complication are known to be at higher risk of recurrent
      thrombotic events despite INR values in the therapeutic range. It ist also known that
      antiphospholipid antibodies can interfere with phospholipid-dependent tests (e.g.
      prothrombin time and INR).

      The primary objective of this study is to determine the prevalence of interfering
      antiphospholipid antibodies. The intensity of anticoagulant therapy was assessed by
      measuring the INR using different thromboplastins and the CoaguChek system for INR
      self-assessment. Test results were compared to measurements of the phospholipid-independent
      chromogenic factor X.

      The second objective of this study is to evaluate the incidence of recurrent thrombotic
      events during 1-year follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2011</start_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Difference between INR and CFX correlate &gt;20%</measure>
    <time_frame>0, 1, 2, 3, 6 and 12 month</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arterial or venous thrombosis</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Any arterial of venous thrombosis occurring under anticoagulant treatment with vitamin-K antagonists during 1-year follow-up</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Antiphospholipid Syndrome</condition>
  <arm_group>
    <arm_group_label>APS patients</arm_group_label>
    <description>Patients with antiphospholipid syndrome requiring long-term anticoagulant therapy with vitamin-K antagonists</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Patients without antiphospholipid antibodies requiring anticoagulant therapy with vitamin-K antagonists</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma samples.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with antiphospholipid syndrome requiring long-term treatment with vitamin-K
        antagonists (N=40) Pateints without antiphospholipid antibodies treated with vitamin-K
        antagonists (N=100)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18-90 years

        Exclusion Criteria:

          -  none
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Birgit Linnemann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Goethe University Hospital, Division of Vascular Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Birgit Linnemann, MD</last_name>
    <phone>+49 (0)69 6301</phone>
    <phone_ext>6096</phone_ext>
    <email>Birgit.Linnemann@kgu.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Edelgard Lindhoff-Last, MD</last_name>
    <phone>+49 (0)69 6301</phone>
    <phone_ext>5096</phone_ext>
    <email>lindhoff-last@em.uni-frankfurt.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Goethe University Hospital</name>
      <address>
        <city>Frankfurt/Main</city>
        <state>Hessen</state>
        <zip>D-60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Birgit Linnemann, MD</last_name>
      <phone>+49 (0)69 6301</phone>
      <phone_ext>6096</phone_ext>
      <email>Birgit.Linnemann@kgu.de</email>
    </contact>
    <contact_backup>
      <last_name>Edelgard Lindhoff-Last, MD</last_name>
      <phone>+49 (0)69 6301</phone>
      <phone_ext>5096</phone_ext>
      <email>lindhoff-last@em.uni-frankfurt.de</email>
    </contact_backup>
    <investigator>
      <last_name>Birgit Linnemann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.gefaesszentrum-frankfurt.de/forschung.php</url>
    <description>Click here for more information about this study: Monitoring Anticoagulant Therapy in Antiphospholipid Syndrome</description>
  </link>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 6, 2012</lastchanged_date>
  <firstreceived_date>August 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospitals</investigator_affiliation>
    <investigator_full_name>Birgit Linnemann</investigator_full_name>
    <investigator_title>Priv.-Doz. Dr. Birgit Linnemann</investigator_title>
  </responsible_party>
  <keyword>Antiphospholipid syndrome</keyword>
  <keyword>Antiphospholipid antibodies</keyword>
  <keyword>Vitamin-K antagonists</keyword>
  <keyword>International normalized ratio</keyword>
  <keyword>Chromogenic factor X</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antiphospholipid Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anticoagulants</mesh_term>
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Antibodies, Antiphospholipid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
